“…In addition to intervening and removing factors that induce peripheral inflammation, drugs such as ulinastatin ( Kim et al, 2023 ), α2-AR agonists Dex ( Oxlund et al, 2022 ) and guanfacine ( Arnsten et al, 2023 ), cyclooxygenase (Cox) inhibitors ( Weng et al, 2021 ), and lidocaine ( Geng et al, 2023 ) all exert anti-inflammatory or neuroprotective effects to attenuate cognitive impairment through various pathways. Peptides consisting of arginine, valine, leucine, and phenylalanine ( Li T. et al, 2023 ) and proline-rich peptides ( Banasiak-Cieslar et al, 2023 ), as well as neutralizing antibodies, such as anti-IL-17 ( Cristiano et al, 2019 ) and anti-IL-6 ( Hisaoka-Nakashima et al, 2022 ), have also been shown to have a positive effect in limiting inflammation and thus improving cognition.…”